.

Peptide Tirzepatide CAS 2023788-19-2

» Hormone Powder » Peptides » Bodybuilding Peptides » Peptide Tirzepatide CAS 2023788-19-2

  • Specifications
Product Name: Tirzepatide
Synonyms: Tirzepatide;GIP\GLP-1;Tirzepatide (LY3298176);Trizepatide;Gip\GLP-1 Tirzepatide Ly3298176 Peptide;Tilposide;Tirzepatide(GLP-1);terzapitide
CAS: CAS 2023788-19-2
MF: /
MW: /
EINECS: 200-001-8

Tirzepatide Description

Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

Tirzepatide Application

Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems.
Mechanism of action It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake, 4 and reduce body weight in patients with type 2 diabetes.
Pharmacology Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity and is currently under regulatory review as a treatment for adults with type 2 diabetes. It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH) and heart failure with preserved ejection fraction (HFpEF). Studies of tirzepatide in obstructive sleep apnea (OSA) and in morbidity/mortality in obesity are planned as well.

Side effects

The overall safety and tolerability profile of tirzepatide was similar to other incretin-based therapies that have been approved for the treatment of obesity. This said, reported side effects were considerable, especially as dosage levels increased. The most common adverse events were nausea (~30%), diarrhea (~20%), constipation (~15%) and vomiting (~10%).
If tirzepatide gets approved as a both a blood glucose control and anti-obesity agent, it could become a blockbuster drug. However, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles, which have plagued similar treatments.

Peptides List

Notes: Click product to reach the product page

NO. Name Packing / CAS
T-A001 MGF 2mg / 5mg
T-A002 PEG MGF 2mg
T-A005 PT-141 (Brmelanotice) 10mg
T-A006 Melanotan-1 (MT-1) 10mg
T-A007 Melanotan-II (MT-2) 10mg
T-A009 GHRP-6 5mg / 10mg
T-A0010 Ipamorelin 2mg
T-A0013 Oxytocin 1g / 2mg
T-A0015 Pentadecapeptide BPC 157 2mg
T-A0016 HGH Fragment 176-191 2mg / 5mg
T-A0017 IGF-1 LR3 0.1mg / 1mg
T-A0022 DSIP 2mg
T-A0023 Selank 5mg
T-A0024 Epitalon 10mg
T-A0025 AOD-9604 2mg
T-A0026 ACE 031 1mg
T-A0027 GDF-8 (Myostatin) 1mg (-20ºC)
T-A0029 Semaglutide 2mg  /5mg /10mg
T-A0030 Follistatin 344 1mg (-20ºC)
T-A0033 Argireline 1g
T-A0035 SNAP-8 1mg

Enquiry Form ( we will get back you as soon as possible )

Name:
*
Email:
*
Message:

Verification:
3 + 3 = ?

Maybe you like also